⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AXSM News
Axsome Therapeutics, Inc
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
globenewswire.com
AXSM
XBOW任命WonLae Lee為韓國區總經理
businesswire.com
GOOG
MSFT
AMZN
META
NVDA
IBM
ORCL
CSCO
ADBE
CRM
INTC
AMD
QCOM
MU
AMAT
LRCX
KLAC
TXN
ADI
NXPI
ON
MPWR
AEHR
TER
ASML
AMGN
GILD
BIIB
REGN
VRTX
BMY
PFE
MRK
JNJ
ABBV
LLY
XOM
CVX
SHEL
BABA
JD
NTES
PDD
VIPS
HTHT
BEKE
EDU
RLX
LI
XPEV
NIO
CPT
TCOM
RBLX
TTD
MELI
PYPL
COIN
HOOD
UPST
SOFI
AFRM
PLTR
SNOW
DDOG
CRWD
PANW
FTNT
OKTA
CHKP
FFIV
HPQ
DELL
HPE
ACN
CGC
ACB
TLRY
CRON
OGI
SPCE
RKLB
ASTS
PLD
AMT
EQIX
CCI
SBAC
TMUS
VZ
EA
TTWO
U
CRSP
EDIT
NTLA
AZN
BNTX
MRNA
TMO
DHR
GOOGL
AAPL
TSLA
NFLX
DIS
CMCSA
PEP
KO
MCD
WMT
COST
TGT
HD
LOW
CHTR
T
SBUX
NKE
MGM
LVS
WYNN
CCL
RCL
NCLH
AAL
UAL
DAL
LUV
BA
GD
LMT
RTX
NOC
HON
GE
MMM
CAT
DE
AGCO
CNH
IR
SNA
TT
ETN
ROK
EMR
AXP
V
MA
BAC
JPM
WFC
C
GS
MS
SCHW
USB
PNC
BBT
STI
KEY
FITB
HBAN
RF
ZION
AXSM
ALKS
TEVA
BMRN
IDXX
EL
LULU
CPRI
PVH
RL
KSS
BBY
DLTR
DG
TJX
ROST
ULTA
MDT
SYK
ISRG
EW
ABT
BSX
XRAY
CTAS
PAYX
ADP
FIS
FISV
Global Sleep Apnea Devices Market is Expected to Cross the USD 15 Billion Mark by 2032 | DelveInsight
globenewswire.com
LULU
LIVN
AXSM
TAK
JAZZ
VNDA
LLY
AVDL
Global Sleep Apnea Devices Market is Expected to Cross the USD 15 Billion Mark by 2032 | DelveInsight
globenewswire.com
LULU
LLY
AXSM
JAZZ
TAK
AVDL
RMD
VNDA
INSM
Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia
globenewswire.com
AXSM
7MM Autism Spectrum Disorder Market Opportunity Assessment and Forecast Report 2024-2034: Entry of the Five Pipeline Products Will Have a Significant Impact on the Market
globenewswire.com
ABR
LLY
PFG
MRK
JNJ
CL
AXSM
ACAD
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
globenewswire.com
AXSM
Global Sleep Tech Devices Market Poised for Strong Growth at a CAGR of ~17% by 2032, Driven by Rising Sleep Disorder Prevalence | DelveInsight
globenewswire.com
RMD
AXSM
JAZZ
AVDL
LLY
VNDA
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
globenewswire.com
AXSM
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
globenewswire.com
AXSM